| Advances in pain management | 1 | Sunith Himantha Atukorale | Beyond Nociception: Unmasking Neuropathic and Mixed Pain Phenotypes in Rheumatoid Arthritis, Osteoarthritis, and Spondyloarthritis | 1 | A |
| Advances in pain management | 2 | Asif Islam | Intra-articular Corticosteroid Injections with Lidocaine versus Bupivacaine in Knee Osteoarthritis: A Systematic Review of Short- and Mid-term Analgesic Outcomes | 1 | A |
| Advances in pain management | 3 | Jiyun Kim | Heterogeneous Clinical and Electrodiagnostic Features of Ganglion Cyst-Related Ulnar Neuropathy | 1 | A |
| Advances in pain management | 4 | Smruti Ramteke | Economic Burden of RA | 1 | A |
| Advances in pain management | 5 | Abdurrahman Soner Senel | Intra-Articular Infliximab Injectionin in Patients With Resistant Monoarthritis And The Demographic Characteristics of the Patients | 1 | A |
| Advances in pain management | 6 | ATSUO UEFUJI | Factors affecting the postoperative decline in ADL of patients with proximal femoral fractures who lived at home before injury | 1 | A |
| Allied health: alternative medicine | 7 | Si Yu Ong | Professor Fang Ding-ya’s Si Miao Xiao Bi Decoction for Rheumatoid Arthritis: Theoretical Basis, Pharmacological Mechanisms, and Clinical Evidence | 1 | A |
| Allied health: alternative medicine | 8 | Su An Quek | Traditional Chinese Medicine (TCM) management of Lupus Nephritis and Herb Drug Interaction (HDI) considerations | 1 | A |
| Antiphospholipid syndrome | 9 | Samar Al Emadi | Validity of the 2023 ACR/EULAR Antiphospholipid Classification Criteria Compared with the Revised Sapporo Criteria in patients with APS in Qatar. | 1 | A |
| Antiphospholipid syndrome | 10 | Yousef Al Rimawi | The prevalence of Non-Conventional Antibodies in Antiphospholipid Syndrome: A case-control study | 1 | A |
| Antiphospholipid syndrome | 11 | Eladio G. V Anino | Triple-Positive Antiphospholipid Syndrome Presenting as Chronic Kidney Disease | 1 | A |
| Antiphospholipid syndrome | 12 | Rossana Carmela Bella | Severe Thrombotic Antiphospholipid Syndrome Mimicking Catastrophic APS: A Case Report | 1 | A |
| Antiphospholipid syndrome | 13 | Pannipa Bupparenoo | Clinical Spectrum and Antibody Profiles in Patients with Antiphospholipid Antibody Positivity: A Real-World Study | 1 | A |
| Antiphospholipid syndrome | 14 | Merhejay Carreon | Catastrophic Antiphospholipid Syndrome: Clinical Spectrum And Outcomes In A Resource-Limited Setting | 1 | A |
| Antiphospholipid syndrome | 15 | Yuhan Chang | Cytokine profiling reveals distinct inflammatory clusters and clinical correlations in antiphospholipid syndrome | 1 | A |
| Antiphospholipid syndrome | 16 | Muhammad Rasyid Este | Antiphospholipid Syndrome Associated with Systemic Lupus Erythematosus in Pregnancy: A Case Report | 1 | A |
| Antiphospholipid syndrome | 18 | Johnson Nameirakpam | Clinical expression of Antiphospholipid antibodies in Systemic Lupus Erythematosus patients in a Tertiary Care Centre of North-East India | 1 | A |
| Antiphospholipid syndrome | 19 | Soumyajit Nandi | Beyond Classical APLA: Cerebral Venous Thrombosis Associated with Isolated IgA Anti-β2 Glycoprotein Antibody and IgA Nephropathy | 1 | A |
| Antiphospholipid syndrome | 20 | Dikshaladevi Nisanthan | Navigating a double edged sword : a case of SLE associated Lupus anticoagulant hypoprothrombinemia syndrome | 1 | A |
| Antiphospholipid syndrome | 21 | Tatiana Reshetnyak | Serum calprotectin in primary antiphospholipid syndrome (PAPS) | 1 | A |
| Antiphospholipid syndrome | 22 | Ha-hee Son | Validation and Comparison of 2023 ACR/EULAR Criteria for Antiphospholipid Syndrome: A Multicenter Study | 1 | A |
| Antiphospholipid syndrome | 23 | Xiaohan Wei | Development of an Integrated Clinical Prediction Model and Novel Histopathological Scoring System for Antiphospholipid Syndrome – Associated Nephropathy | 1 | A |
| Antiphospholipid syndrome | 24 | zhixia Yang | Residual marrow IGHG⁺ plasma cells underlie incomplete antiphospholipid IgG suppression during BAFF–APRIL blockade in antiphospholipid syndrome | 1 | A |
| Antiphospholipid syndrome | 25 | Shuyi Yu | ISR-ATF4-Driven Endothelial Senescence Coordinates with a Pathogenic Immunoglobulin-Secreting Niche to Drive Vascular Remodeling in APSN | 1 | A |
| Antiphospholipid syndrome | 26 | Jiuliang Zhao | Antiphospholipid antibodies titers trajectories and adverse pregnancy outcomes: a longitudinal cohort study | 1 | A |
| Antiphospholipid syndrome | 27 | Jiuliang Zhao | Clinical and imaging characterization of antiphospholipid antibody-associated pancreatic diseases | 1 | A |
| Antiphospholipid syndrome | 28 | Jiuliang Zhao | Risk-Stratified Outcomes of Rivaroxaban Versus VKAs in Antiphospholipid Syndrome: A Real-World Study | 1 | A |
| Autoinflammatory diseases | 29 | Shahad Alansari | Chronic Nonbacterial Osteomyelitis With Unusual Associations in Children: A Case Series | 1 | A |
| Autoinflammatory diseases | 30 | Ekaterina I. Alekseeva | Clinical and laboratory manifestations and therapy in children with various variants in the tnfrsf1a gene. | 1 | A |
| Autoinflammatory diseases | 31 | Noora Almajed | Expanding the Phenotypic and Genetic Landscape of Zinc-Finger NFX1-type containing 1 (ZNFX1): Novel Clinical Spectrum | 1 | A |
| Autoinflammatory diseases | 32 | Ozge Altug Gucenmez | Is Infantile Colic More Common in Children with Familial Mediterranean Fever | 1 | A |
| Autoinflammatory diseases | 33 | Ozge Altug Gucenmez | Clinical Comparison of Homozygous and Compound Heterozygous MEFV Mutations in Childhood FMF: A Single-Center Experience | 1 | A |
| Autoinflammatory diseases | 34 | Ekaterina Bandurko | Adult chronic recurrent multifocal osteomyelitis (CRMO): clinical presentation, comorbidity profile and treatment outcomes | 1 | A |
| Autoinflammatory diseases | 35 | Mariia Beketova | The Russian cohort of patients with PFAPA syndrome and carriers of the MEFV gene's variants | 1 | A |
| Autoinflammatory diseases | 36 | Manikandan Chidambaram | VEXAS syndrome: Clinical variability and the importance of high-depth sequencing - Lessons from two cases | 1 | A |
| Autoinflammatory diseases | 37 | Mahendra Dhaka | Beyond steroid myopathy: dermatomyositis sine dermatitis with celiac disease and restrictive cardiomyopathy presenting as progressive pure motor quadriparesis | 1 | A |
| Autoinflammatory diseases | 38 | Bing Jian Ding | Orbital Myositis and Optic Perineuritis as Novel Manifestations of DADA2: Case Report and Systematic Review | 1 | A |
| Autoinflammatory diseases | 39 | Bhavini Dodia | Secondary Hemophagocytic Lymphohisiocytosis in Anti-PL12 Antisynthetase Syndrome presenting as persistent fever | 1 | A |
| Autoinflammatory diseases | 40 | Madhu Edirisinghege | Still Refractory: JAK-ing Up the Treatment of Adult-Onset Still Disease in the Setting of a Pathogenic Perforin Variant | 1 | A |
| Autoinflammatory diseases | 41 | Jing Gao | A novel recycling anti‑TL1A × anti‑IL‑23 bispecific antibody with extended half‑life for the treatment of inflammatory bowel disease | 1 | A |
| Autoinflammatory diseases | 42 | Jieun Han | Anti-psoriatic effects of germanium telluride nanosheets on the M5-induced HaCaT keratinocytes and psoriasis mouse model | 1 | A |
| Autoinflammatory diseases | 43 | Jieun Han | Therapeutic potential of adipose-derived mesenchymal stem cell secretome in psoriasis-like in vivo and in vitro models | 1 | A |
| Autoinflammatory diseases | 44 | Misako Higashida Konishi | Real-world glucocorticoid treatment patterns, outcomes, and hepatic inflammatory manifestations in polymyalgia rheumatica: a retrospective single-center study in Japan | 1 | A |
| Autoinflammatory diseases | 45 | Kento Ichikawa | Cross-cohort transcriptomic heterogeneity of interferon signaling and relatively robust neutrophil metabolic-stress programs in adult-onset Still’s disease | 1 | A |
| Autoinflammatory diseases | 46 | Fengyun Jia | The pathogenic role of anti-MDA5 autoantibodies in MDA5 antibody-positive dermatomyositis | 1 | A |
| Autoinflammatory diseases | 47 | Alida Karibova | The efficacy of levilimab in patients with MEFV-associated autoinflammatory syndrome and secondary AA amyloidosis of the kidneys | 1 | A |
| Autoinflammatory diseases | 48 | alireza Khabbazi | Comparative Performance of Existing Classification Criteria for Adult-Onset Still Disease | 1 | A |
| Autoinflammatory diseases | 49 | Hyun-Sook Kim | Effects of nerandomilast on plasma protein biomarkers in patients with progressive pulmonary fibrosis (PPF) | 1 | A |
| Autoinflammatory diseases | 50 | Hyun-Sook Kim | Predicting long-term survival benefit of nerandomilast in patients with progressive pulmonary fibrosis (PPF) | 1 | A |
| Autoinflammatory diseases | 51 | Ji-Won Kim | Multicenter retrospective analysis of leflunomide efficacy and safety in adult-onset Still’s disease | 1 | A |
| Autoinflammatory diseases | 53 | Ravi Kumar U | Clinical Profile and Predictors of Outcomes in Adult-Onset Still’s Disease: A Single-Center Study from India | 1 | A |
| Autoinflammatory diseases | 54 | Mihye Kwon | Machine Learning–Based Prediction of One-Year Mortality in Adult-Onset Still’s Disease Using the Korean National Health Insurance Service Database | 1 | A |
| Autoinflammatory diseases | 55 | Sangwon Lee | Plasticity of Small Intestinal CD25lowFoxp3+ Tregs into Pathogenic Th17 Cells in Rheumatoid Arthritis | 1 | A |
| Autoinflammatory diseases | 56 | Shang Ming Samuel Lee | A Case Series of Adolescent and Adult-Onset Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA) from Singapore | 1 | A |
| Autoinflammatory diseases | 57 | Shang Ming Samuel Lee | Spectrum of Adult Autoinflammatory Diseases in a Tertiary Rheumatology, Allergy and Immunology Service in Singapore: A Single-Centre Cohort | 1 | A |
| Autoinflammatory diseases | 58 | Sun-mi Lee | Quantitative Severity Assessment and Early Diagnosis of Rheumatoid Arthritis Using TNF-α–Targeting Gold Nanorods | 1 | A |
| Autoinflammatory diseases | 59 | Yogeshwar Makanji | Nipocalimab for Warm Autoimmune Hemolytic Anemia: Results from the Phase 2/3 Randomized Double-blind ENERGY Study | 1 | A |
| Autoinflammatory diseases | 60 | Aditya Melti | Autoimmune Hepatitis–Primary Sclerosing Cholangitis Overlap: A Diagnostic Challenge in Autoimmune Liver Disease Spectrum | 1 | A |
| Autoinflammatory diseases | 61 | Khilola Mirakhmedova | Predicting the risk of cardiovascular complications of cardiovascular pathology in patients with psoriatic arthritis | 1 | A |
| Autoinflammatory diseases | 62 | Mandana Nikpour | Efficacy of nerandomilast in patients with autoimmune interstitial lung diseases and progressive pulmonary fibrosis in the FIBRONEER-ILD trial | 1 | A |
| Autoinflammatory diseases | 63 | Mandana Nikpour | Safety and tolerability of nerandomilast in patients with autoimmune disease–related progressive pulmonary fibrosis in the FIBRONEER-ILD trial | 1 | A |
| Autoinflammatory diseases | 64 | Maryam Noory | Pediatric eosinophilic granulomatosis with polyangiitis: a 10-year case series highlighting neurologic and cardiac manifestations | 1 | A |
| Autoinflammatory diseases | 65 | Mohd Hakimi Nordin | Extrapyramidal Symptoms (EPS) with parkinsonism-like features in Adult-Onset Still’s Disease | 1 | A |
| Autoinflammatory diseases | 66 | Shalene Palansamy | Multisystem sarcoidosis masquerading as mixed connective tissue disease: a diagnostic challenge | 1 | A |
| Autoinflammatory diseases | 67 | Faisal Qaderi | Clinical Profile and Subtype of Patients with Idiopathic Inflammatory Myopathies: A Retrospective Multi-Center Cohort Study | 1 | A |
| Autoinflammatory diseases | 68 | Yulu Qiu | PCDH18 Links Genetic Susceptibility to Fibroblast Activation in Anti- MDA5-Positive Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease | 1 | A |
| Autoinflammatory diseases | 69 | Haili Shen | Rheumatology-Related Serological Markers and Adverse Pregnancy Outcomes: A Single-Centre Real-World Cohort Study | 1 | A |
| Autoinflammatory diseases | 70 | Chuanyin Sun | Machine Learning-Based Early Identification of Macrophage Activation Syndrome in Adult-Onset Still’s Disease | 1 | A |
| Autoinflammatory diseases | 71 | Elena Taskina | Clinical and Genetic Characteristics of 8 Russian Patients with VEXAS Syndrome | 1 | A |
| Autoinflammatory diseases | 72 | Elena Taskina | Relapsing polychondritis with chondromalacia: clinical characteristics and association with more severe disease | 1 | A |
| Autoinflammatory diseases | 73 | Serdal Ugurlu | Goflikicept for familial Mediterranean fever: efficacy and safety results from an international randomized clinical trial | 1 | A |
| Autoinflammatory diseases | 74 | Jiwon Yang | Predictors of Intermediate Target Achievement in a Treat-to-Target Strategy for Adult-Onset Still’s Disease: A Multicenter Study | 1 | A |
| Autoinflammatory diseases | 75 | Junna Ye | Identification of a metabolic-immune crosstalk in Still’s disease: monocyte/macrophage-derived immunometabolite itaconate dictates hepatic immunopathology via CXCL10-CD8 T-cell axis | 1 | A |
| Autoinflammatory diseases | 76 | Valeriya Yudina | Cytokine levels in sJIA patients | 1 | A |
| Autoinflammatory diseases | 77 | Valeriya Yudina | Hemophagocytic lymphohistiocytosis in children: predictors of lethal outcome | 1 | A |
| Autoinflammatory diseases | 78 | Quan Zhou | Recognizing the Airway-Predominant Phenotype of Relapsing Polychondritis: a Retrospective Observational Study | 1 | A |
| Autoinflammatory diseases | 79 | Zhenping Zhu | Design and Preclinical Development of a Bispecific Antibody Targeting TL1A and IL11 for Inflammatory and Fibrotic Diseases | 1 | A |
| Autoinflammatory diseases | 80 | Zhenping Zhu | Development of a BAFFR×CD3 T Cell Engager for B Cell–Driven Autoimmune Diseases | 1 | A |
| Autoinflammatory diseases | 81 | Zhenping Zhu | Preclinical Characterization of a Potent, Half-life–Extended Anti-IL1RAP Antibody | 1 | A |
| Autoinflammatory diseases | 82 | Zhenping Zhu | Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody for Systemic Autoimmune and Rheumatic Diseases | 1 | A |
| Autoinflammatory diseases | 83 | Zhenping Zhu | Preclinical Development of an OX40L/IL31 Bispecific Antibody for Chronic Inflammatory Skin Diseases | 1 | A |
| Big data | 84 | Khalid Alnaqbi | Vaccination Knowledge, Attitudes, and Uptake Among Patients with Rheumatic Diseases Across Arabian Gulf Countries | 1 | A |
| Big data | 85 | Jang Ho Doo | Impact of Gout and Allopurinol Medication Adherence on Osteoporotic Fracture Risk: A Nationwide Population-Based Cohort Study | 1 | A |
| Big data | 86 | Aayush Dukiya | Do Biologics Increase Infection Risk in Autoimmune Rheumatic Diseases? A Prospective Study from high endemic setting | 1 | A |
| Big data | 87 | Takayuki Fujii | Development and Internal-External Validation of AI Model for Predicting Rheumatoid Arthritis Flare: An ANSWER Cohort Study | 1 | A |
| Big data | 88 | YuSeon Jung | Immune-Related Adverse Events and Survival in Rheumatoid Arthritis Patients Treated with Immune Checkpoint Inhibitors: A Nationwide Matched Cohort Study | 1 | A |
| Clinical immunology related to rheumatic diseases | 89 | Kosar Asna Ashari | RASGRP1 Deficiency Manifesting as Severe Vasculopathy and Refractory Autoimmunity: A Case Report and Systematic Review | 1 | A |
| Clinical immunology related to rheumatic diseases | 90 | Akerke Auanassova | Diagnostic Delay in Systemic Vasculitis: A Multinational Mixed-Methods Real-World Study | 1 | A |
| Clinical immunology related to rheumatic diseases | 91 | Riju Bhattacharjee | Macrophage Activation Syndrome in Childhood: A Nightmare A Single-Centre Prospective Observational Study | 1 | A |
| Clinical immunology related to rheumatic diseases | 92 | Tien Ming Chan | Do ANA Patterns Matter in Fibromyalgia? A Large Hospital-Based Cohort Study | 1 | A |
| Clinical immunology related to rheumatic diseases | 93 | Tien Ming Chan | The Homogeneous Nuclear ANA Pattern Identifies a Selective Autoimmune Phenotype: A Cross-Sectional Comparison with ANA-Negative and Other ANA-Positive Patients | 1 | A |
| Clinical immunology related to rheumatic diseases | 94 | Shenshen Chen | PD-1+CD8+ T cells are hyperactivated and associated with refractory systemic lupus erythematosus | 1 | A |
| Clinical immunology related to rheumatic diseases | 95 | Yuqing Chen | Sema4A Orchestrates B Cell-Synovial Fibroblast Crosstalk to Promote Rheumatoid Arthritis | 1 | A |
| Clinical immunology related to rheumatic diseases | 96 | Yushiro Endo | Alternative Pathway–Driven Complement Activation in TAFRO Syndrome: Integrated Evidence from Serum, Proteomics, and Renal Pathology | 1 | B |
| Clinical immunology related to rheumatic diseases | 97 | Jiyoung Jeong | Interim Ph1 Results for SPY072, a Novel Half-Life Extended mAb Targeting TL1A, Suggest Potential Q3-Q6M Maintenance Dosing for Rheumatic Disease | 1 | B |
| Clinical immunology related to rheumatic diseases | 98 | Jenny Jiang | Safety and B-cell depletion with cizutamig, a BCMA×CD3 T-cell engager, in autoimmune diseases | 1 | B |
| Clinical immunology related to rheumatic diseases | 99 | Wanruchada Katchamart | Intravenous Immunoglobulin in the Treatment of Autoimmune Rheumatic Diseases and Vasculitides: A Systemic Review and Meta-analysis of Efficacy and Safety | 1 | B |
| Clinical immunology related to rheumatic diseases | 100 | Di Rui Ke | IL-6-Specific STAT3–BRD4 Co-Condensation Drives Anabolic Reprogramming in Rheumatoid Arthritis Synovial Lymphocytes: A Multi-Omics Study | 1 | B |
| Clinical immunology related to rheumatic diseases | 101 | Zumrad Khamroeva | Clinical and Demographic Predictors of Poor Outcomes in Immunoinflammatory Rheumatic Diseases: Insights from a Tajikistan Cohort | 1 | B |
| Clinical immunology related to rheumatic diseases | 102 | Zumrad Khamroeva | Inflammatory Biomarkers and Their Association with Atrial Fibrillation in Rheumatic Heart Disease | 1 | B |
| Clinical immunology related to rheumatic diseases | 103 | Tomohiro Koga | Integrated multi-omics profiling identifies distinct molecular signatures and a severity-linked latent factor in TAFRO syndrome | 1 | B |
| Clinical immunology related to rheumatic diseases | 104 | Manjari Lahiri | Latent Class Analysis of the Thymus-Index Predicts Effectiveness but not Toxicities in Immune Checkpoint Inhibitor-Induced Myasthenia Gravis, Myocarditis and/or Myositis | 1 | B |
| Clinical immunology related to rheumatic diseases | 105 | Xue Li | Low-Dose IL-2 for a Neuroimmune Disease: Therapeutic Efficacy and Immunological Mechanisms in Neuromyelitis Optica Spectrum Disorder | 1 | B |
| Clinical immunology related to rheumatic diseases | 106 | Shihchang Lin | Dysregulated Monocyte Subset Activation and Chemokine–Chemokine Receptor Expression in Systemic Lupus Erythematosus | 1 | B |
| Clinical immunology related to rheumatic diseases | 107 | Xianming Long | Prevalence and Disability-Adjusted Life Years Due to Musculoskeletal Disorders in Aged 50 and Over for 204 Countries and Territories 1990–2021 | 1 | B |
| Clinical immunology related to rheumatic diseases | 108 | Khilola Mirakhmedova | Modern perspectives on the clinical course of early seronegative rheumatoid arthritis | 1 | B |
| Clinical immunology related to rheumatic diseases | 109 | Yusuke Miyashita | Mechanisms Mediating Synovial Resident Memory T Cell Persistence in Rheumatoid Arthritis | 1 | B |
| Clinical immunology related to rheumatic diseases | 110 | Yasuo Nagafuchi | Baseline CD8+CCR4+CD25+ T-cell subset predicts abatacept response in rheumatoid arthritis | 1 | B |
| Clinical immunology related to rheumatic diseases | 111 | Jun Nakamura | IP-10/MIG Ratio as a Biomarker Distinguishing Type I and Type II Interferonopathies: Anti-MDA5 Dermatomyositis versus Adult-Onset Still's Disease | 1 | B |
| Clinical immunology related to rheumatic diseases | 112 | Shalene Palansamy | Dual pathologies: the uncommon overlap of iga vasculitis and rheumatoid arthritis | 1 | B |
| Clinical immunology related to rheumatic diseases | 113 | Tatiana Panafidina | Autoantibody profiles in patients with systemic lupus erythematosus | 1 | B |
| Clinical immunology related to rheumatic diseases | 114 | Ramaswamy Subramanian | Trabecular Bone Score and Bone Mineral Density in Systemic Lupus Erythematosus: A Cross-Sectional Study | 1 | B |
| Clinical immunology related to rheumatic diseases | 115 | Naonobu Sugiyama | Pooled Safety Analysis of Zola-cel, a Chimeric Antigen Receptor T Cell Therapy, in Refractory Autoimmune Diseases: Phase 1 Studies Update | 1 | B |
| Clinical immunology related to rheumatic diseases | 116 | Naveen Keerthi Tamilmani | Autoimmune Etiologies in Chronic Non-Healing Ulcers: A 5-Year Retrospective Analysis from a Tertiary Care Centre | 1 | B |
| Clinical immunology related to rheumatic diseases | 117 | Megha Unni | More Than Meets the Eye: Clinical, Etiological, and Immunological Profile of Uveitis in Rheumatology Practice | 1 | B |
| Clinical immunology related to rheumatic diseases | 118 | George Woodward | Double Negative CD19+IgD-CD27- T-bet+ B cells in SLE pregnancy: BLOOM study (B cell lineages and obstetric outcomes in maternal SLE) | 1 | B |
| Clinical immunology related to rheumatic diseases | 119 | Junna Ye | Mapping Bone Marrow Immune Cell Atlas in Systemic Lupus Erythematosus Patients | 1 | B |
| Clinical immunology related to rheumatic diseases | 120 | Jina Yeo | Differential Inflammasome Activation According to HLA-B27 Status in Axial Spondyloarthritis | 1 | B |
| Clinical immunology related to rheumatic diseases | 122 | Nurul Aulia Zakaria | Elevated IgE and Eosinophilia in Rheumatology Practice: Diagnostic Pitfalls in Type 2 Immune Dysregulation Mimicking Connective Tissue Disease | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 123 | Ahmed Abdulbari | Epidemiology of Fracture Categories in Iraq: A Three-Year Population-Based Multicenter Registry Study. | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 125 | Annie Rose Ammar | Development and initial validation of Gouty Arthritis Self-Management Education (GSM) tool for Filipinos: Phase 1 | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 126 | Shazia Anwar | Polymyalgia Rheumatica: Clinical Profile and Disease Spectrum at a Rheumatology Centre in Lahore Pakistan | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 127 | Berkan Armagan | Hydroxychloroquine Discontinuation in Rheumatic Diseases: Retinal Toxicity and Gaps in Clinical Monitoring | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 128 | Sunith Himantha Atukorale | Complementary Medicine Use, Non-Disclosure, and Prescribed Treatment Discontinuation in Rheumatoid Arthritis and Osteoarthritis: A Cross-Sectional Analysis in Sri Lanka | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 129 | Sunith Himantha Atukorale | Cross-Sectional Survey of Corticosteroid Knowledge and Self-Management in Rheumatology Patients | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 130 | Riju Bhattacharjee | Health Related Quality of Life of Indian Children with Rheumatological Diseases: A Questionnaire-Based Prospective Study | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 131 | Alyssa Bunag | Indications for Antinuclear Antibody (ANA) Testing Among Non-Rheumatology Physicians: A Knowledge, Attitudes, and Practices (KAP) Study | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 132 | Se Rim Choi | The Korean Rheumatoid Arthritis Fact Sheet Project II: Nationwide 15-Year Trends in Healthcare Utilization and Costs, 2010-2024 | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 133 | Liudmila Garzanova | Mortality Burden in Systemic Sclerosis: A Systematic Review, Meta-Analysis, and Meta-Regression Modelling of Russian Population-Level Estimates | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 134 | Tayyeba Khursheed Ahmed | Active Disease Drives Adverse Pregnancy Outcomes in Women with Rheumatic Diseases: Results from a Cross-Sectional Observational Study from Pakistan | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 135 | Tayyeba Khursheed Ahmed | High-Risk Teratogenic Exposure Due to Inadequate Contraceptive Knowledge and Use Among Women with Rheumatic Diseases in Pakistan | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 136 | Yongbum Kim | Real-world Effectiveness of Zoster Vaccine in Rheumatoid Arthritis Patients Initiating Janus Kinase Inhibitors: A Single-Center Korean Cohort Study | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 138 | Seung-geun Lee | Clinical Outcomes in Patients with Rheumatoid Arthritis Initiating Biologic or Targeted Synthetic DMARDs According to Residential and Treating Hospital Location | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 139 | Zhixiu Li | 24-Hour Movement Composition and Rheumatoid Arthritis Risk: Evidence from Isotemporal Substitution and Counterfactual Modeling | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 140 | Zaferulla Khan Mariyam Jezeema | An audit on retinopathy screening in patients on hydroxychloroquine for rheumatological causes at the rheumatology clinic (Unit C), NHSL | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 141 | Binish Haseeb Mukry | A Clinical Audit of Rheumatoid Arthritis Management: Adherence to NICE and EULAR Guidelines in a Tertiary Care Setting | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 142 | Binish Haseeb Mukry | Compliance with EULAR and NICE Guidelines in Rheumatoid Arthritis: A Clinical Audit of Monitoring Practices | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 143 | Chun Ruh Ng | Referral Behaviour of Primary Care Doctors to a Rheumatology Clinic in Malaysia | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 144 | Yoon-Jeong Oh | Sex-specific association between serum uric acid levels and sarcopenia in Korean adults: 2022–2023 Korea National Health and Nutrition Examination Survey | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 145 | Shahida Perveen | Prevalence and factors associated with Burnout Amongst Rheumatologists: A Cross-Sectional Survey | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 146 | Talib Tahir | Reducing Patient Waiting Time in a Private Rheumatology Practice: A Clinical Audit | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 147 | Sasheela Ubhayasiri | Patient-Initiated Follow-Up in Rheumatology: A 3-Year Retrospective Analysis of Outcomes, Risk Factors, and Pathway Optimization | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 148 | Naeem Ullah | Trends in Giant Cell Arteritis-Associated Mortality in the US, 1999–2024: A Population-Based Analysis of the CDC WONDER MCD Database | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 149 | Sithayarat Uthaiphan | Incidence and prevalence of psoriatic arthritis in Thailand | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 150 | Mitsuru Watanabe | Real-World Impact of JAK Inhibitors, Recombinant Zoster Vaccine, and Prior Infection on Herpes Zoster Risk: A Time-Dependent Covariate Analysis | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 151 | Sabrina Yesmin | Association of Glycemic Status and Musculoskeletal Pain Patterns in Diabetic Adults: A Cross-Sectional Study from Bangladesh | 1 | B |
| Epidemiology, COPCORD, health care system and pharmacoeconomics | 152 | Alan Zhou | Language Accessibility of Rheumatologists in Ontario, Canada: A Population-Based Repeated Cross Sectional Study | 1 | B |
| Fibromyalgia | 153 | supatta Chaiprasert | Prevalence and factors associated with fibromyalgia in hand osteoarthritis | 1 | B |
| Fibromyalgia | 154 | Timothy Chong | The impact of Fibromyalgia on disability and quality of life in a multi-ethnic psoriatic arthritis population. | 1 | B |
| Fibromyalgia | 155 | Johanda Damanik | Perception and Practice Patterns of Fibromyalgia Among Internists and Rheumatologists in Indonesia: A National Cross-Sectional Survey | 1 | B |
| Fibromyalgia | 156 | Shreya Shrestha | Impact of depression and/or anxiety on clinical phenotype and pharmacological treatments in patients with fibromyalgia | 1 | B |
| Genetics | 157 | Evgeniy Kopylov | From transcript to protein: pronounced activation of AP-1 pathway in fibrodysplasia ossificans progressiva patient-derived cells | 1 | B |
| Genetics | 158 | Mikhail Kostik | Use of low-dose rituximab for immune-mediated complications of Spondylochondrodysplasia with Immune Dysregulation (SPENCD Syndrome) | 1 | B |
| Genetics | 159 | Galymzhan Asylbekovich Togizbayev | Genetic Alleles and Autoantibodies Associated with Systemic Sclerosis Susceptibility in Kazakh Patients | 1 | B |
| Genetics | 160 | Galymzhan Asylbekovich Togizbayev | Genetic Variations and Autoantibody Profile of Systemic Lupus Erythematosus in Kazakhstani Patients | 1 | B |
| Genetics | 161 | Nam Chung Tran | Genetic spectrum of Limb-girdle muscular dystrophy in Vietnamese patients using Next-generation sequencing | 1 | B |
| IgG4 - related disease | 162 | Ridzwan Alias | The Great Mimicker: IgG4-Related Disease Presenting as a Suspected Naso-oropharyngeal Carcinoma | 1 | B |
| IgG4 - related disease | 163 | Shuning Guo | Mortality analysis in patients with IgG4-related disease: a long-term cohort study in China | 1 | B |
| IgG4 - related disease | 164 | Buvaneshwari Kandasamy | IgG4 disease: An uncommon presentation of fibroinflammatory IgG4 disease | 1 | B |
| IgG4 - related disease | 165 | Sourabh Malviya | IgG4-Related Disease in India: A Single-Centre Experience of 36 Patients | 1 | B |
| IgG4 - related disease | 166 | Naina Mehta | When IgG4-Related Disease Defies Convention: A Rare Convergence of FSGS and Immune Thrombocytopenia | 1 | B |
| IgG4 - related disease | 167 | HeeJin Park | The 6-Month Responder Index: A Powerful Predictor of Relapse in IgG4-Related Disease | 1 | B |
| IgG4 - related disease | 168 | Avishek Sarangal | A Rare Presentation of Multi-Organ IgG4 Related Disease presenting with Hypophysitis and Central Hypopituitarism | 1 | B |
| IgG4 - related disease | 169 | Damira Shanarova | Retroperitoneal Fibrosis (Ormond’s Disease) as a Manifestation of IgG4-Related Disease: The Importance of Early Immunosuppressive Therapy and Rheumatologic | 1 | B |
| IgG4 - related disease | 170 | Ruchira Sivakumar | IgG4-Related Disease in Middle Eastern Population: Clinical and PET/CT Characteristics from a Tertiary Cohort | 1 | B |
| IgG4 - related disease | 171 | Ha-hee Son | Clinical features and treatment strategies associated with relapse of biopsy-proven IgG4-related disease: a retrospective multicenter study | 1 | B |
| IgG4 - related disease | 172 | Elena Taskina | IgG4-Related Retroperitoneal Fibrosis: A Russian Single-Center Cohort | 1 | B |
| IgG4 - related disease | 173 | Hung-cheng Tsai | Integrative Analysis of IgG Glycosylation and Immune Profiling Reveals Distinct Pathogenic Mechanisms and Biomarkers for Proliferative and Fibrotic IgG4-Related Disease. | 1 | B |
| IgG4 - related disease | 174 | SUNDEEP UPADHYAYA | IgG4-Related Disease Presenting as an Interatrial Cardiac Mass with Heart Block: A Rare Cardiovascular Manifestation | 1 | B |
| IgG4 - related disease | 175 | SUNDEEP UPADHYAYA | Overlap of PR3-ANCA–Associated Vasculitis and IgG4-Related Disease Presenting with Multiglandular and Sinonasal Involvement: A Diagnostic Challenge | 1 | B |
| IgG4 - related disease | 176 | Carson Chun Yin Yip | Baseline Peripheral Eosinophilia Identifies a Distinct and High-Risk Subset of IgG4-Related Disease: A Multicentre Study | 1 | B |
| Imaging techniques and diagnosis | 177 | S K Jakaria Been Sayeed | Diagnostic Utility of Multisequence Magnetic Resonance Imaging with Vessel Wall Imaging for Detecting Cerebral Vasculitis among Neuropsychiatric Lupus Patients | 1 | B |
| Imaging techniques and diagnosis | 178 | Ho Yin Chung | Deep learning algorithm for semiquantification of spinal inflammation in axial spondyloarthritis | 1 | B |
| Imaging techniques and diagnosis | 179 | Yunus Emre Dalkılıç | Diagnostic Value of Rheumatology Consultation in FUO/IUO: The Predominant Role of Imaging Over Serology | 1 | B |
| Imaging techniques and diagnosis | 180 | Menglin Ding | Segmental Distribution of Characteristic Spinal Syndesmophytes in Ankylosing Spondylitis: A CTSS Evaluation | 1 | B |
| Imaging techniques and diagnosis | 181 | YoungEun Kim | Kidney FDG Uptake as a PET/CT Imaging Feature of Immune-Mediated Glomerulonephritis | 1 | B |
| Imaging techniques and diagnosis | 182 | Mikhail Kostik | Amide proton transfer (APT) CEST MRI of the knee in juvenile idiopathic arthritis: a prospective pilot study | 1 | B |
| Imaging techniques and diagnosis | 183 | Md Nahiduzzamane Shazzad | Relationship Between OMERACT Ultrasound Scores and Kellgren-Lawrence (K-L) Grading in the Evaluation of Knee Osteoarthritis | 1 | B |
| Imaging techniques and diagnosis | 184 | York Kiat Tan | Threshold definitions and adoption of 2017 EULAR-OMERACT scoring of ultrasound synovitis in rheumatoid arthritis: a systematic literature review | 1 | B |
| Imaging techniques and diagnosis | 185 | Saira Yasmin | Evaluating the efficacy of MSK-USG in detecting subclinical synovitis in RA patients who are in clinical remission according to DAS28-ESR | 1 | B |
| Imaging techniques and diagnosis | 186 | Jiawei Zhao | Role of Joint Space Analysis by High-resolution Peripheral Quantitative Computed Tomography in Predicting Inflammatory Arthritis among Patients with Arthralgia | 1 | B |
| Metabolic bone diseases/osteoporosis | 187 | Mustafa Alhayali | Correlation Between Serum Uric Acid Levels and Body Mass Index in a Sample of Iraqi Patients: A Retrospective Cross-Sectional Study | 1 | B |
| Metabolic bone diseases/osteoporosis | 188 | Inna Gaydukova | Osteoporosis Frequency in Celiac Disease vs. Carriers of Gluten Intolerance Genes Without Celiac Disease | 1 | B |
| Metabolic bone diseases/osteoporosis | 189 | M M H Jayasekara | Association between Proximal Femur Geometrical Parameters and Hip Fracture Pattern in Elderly Population that Presented to Sri Lankan Tertiary Care | 1 | B |
| Metabolic bone diseases/osteoporosis | 190 | Kittipong Kaewkarnjanarat | Prevalence and Risk Factors of Glucocorticoid-Induced Osteoporosis in SLE Patients: A Test-Negative design Case-Control Study | 1 | B |
| Metabolic bone diseases/osteoporosis | 191 | Kamil Khayrutdinov | Hypophosphatemic Osteoporosis with Spontaneous Sacral Compression Fracture Mimicking Axial Spondyloarthritis in Patients with Celiac Disease: A Case Report | 1 | B |
| Metabolic bone diseases/osteoporosis | 192 | Kang Kosal | Denosumab and Teriparatide Combination therapy after Denosumab mono therapy in Postmenopausal Osteoporosis on Cambodian Women | 1 | B |
| Metabolic bone diseases/osteoporosis | 193 | Eunju Lee | Region-specific transcriptomic landscape of osteonecrosis of the femoral head: insights from bulk and single-cell RNA-sequencing | 1 | B |
| Metabolic bone diseases/osteoporosis | 194 | Seung Hoon Lee | Co-administration of calcium carbonate or sodium bicarbonate prevents esomeprazole-induced osteoporosis | 1 | B |
| Metabolic bone diseases/osteoporosis | 195 | Hiroto Nakano | A case of mixed connective tissue disease that underwent a potential worsening of cholesteatoma under the use of denosumab | 1 | B |
| Metabolic bone diseases/osteoporosis | 196 | Ken Nakaseko | Acute-Phase Reactions to Inpatient Zoledronic Acid After Surgery for Proximal Femoral Fractures | 1 | B |
| Metabolic bone diseases/osteoporosis | 197 | Anh Ngo | Diagnostic Pitfalls in Tumor-Induced Osteomalacia: A Report of Two Cases | 1 | B |
| Metabolic bone diseases/osteoporosis | 198 | Hoang Thanh Van Nguyen | Assessment of Peak Bone Mineral Density and Its Associated Factors in Vietnamese Adults: A Cross-Sectional Study | 1 | B |
| Metabolic bone diseases/osteoporosis | 199 | Faisal Qaderi | Calcific Periarthritis as a Rare, Colchicine-Responsive Presentation of Adult Hypophosphatasia: A Case-Based Review of the Literature | 1 | B |
| Metabolic bone diseases/osteoporosis | 200 | Akihiro Shiohira | Fracture-Related Factors and the Effect of Osteoporosis Treatment in Patients with Rheumatoid Arthritis | 1 | B |
| Metabolic bone diseases/osteoporosis | 201 | Elena Taskina | Association between sclerostin level and bone mineral density in women with rheumatoid arthritis | 1 | B |
| Metabolic bone diseases/osteoporosis | 202 | Elena Taskina | Bone mineral density and appendicular muscle mass in women with rheumatoid arthritis: associations with uric acid and hyperuricemia | 1 | B |
| Metabolic bone diseases/osteoporosis | 203 | Elena Taskina | Osteosarcopenia in women with rheumatoid arthritis: association with muscle, bone, and adipose tissue biomarkers | 1 | B |
| Metabolic bone diseases/osteoporosis | 204 | Ying Ying | Integrating scRNA‑Seq and bulk RNA‑Seq reveals the glycosylation- and lactylation-related diagnostic genes in gout | 1 | B |
| Metabolic bone diseases/osteoporosis | 205 | Ying Ying | Multi-Omics analysis of Mitochondrial Autophagy-Related Genes in Hyperuricemia and Obesity | 1 | B |
| Metabolic bone diseases/osteoporosis | 206 | Keisuke Yoshida | Atypical Femoral Fractures in Rheumatoid Arthritis: Higher Risk of Delayed Union and the Importance of Early Intervention | 1 | B |
| Precision medicine | 207 | Olga Lomakina | RheumoLag ranking undrugged GWAS targets and drug repurposing signals across eight rheumatologic diseases | 1 | B |
| Precision medicine | 208 | Xianming Long | Dual-Mechanism Inhalable Nanocomposite Restores the Alveolar Mucus Barrier and Enables Deep-Lesion Delivery for Synergistic Treatment of Pulmonary Fibrosis | 1 | B |
| Precision medicine | 209 | Binish Haseeb Mukry | Pharmacogenetic Markers of DMARD Response in Rheumatoid Arthritis: Evidence from GWAS and Genetic variation-based studies | 1 | B |
| Precision medicine | 210 | Md Jannatul Ferdous Parvez | Neoepitope-Specific Blocking of Active IL-18 as a Novel Therapeutic Strategy for Lupus Nephritis: Evidence from MRL/lpr Mice. | 1 | B |
| Precision medicine | 211 | Widya Pratiwi | Precision and Personalized Medicine in Systemic Sclerosis: A Global Bibliometric Analysis | 1 | B |
| Precision medicine | 212 | Widya Pratiwi | Research Trends in Genomics and Personalized Therapy in Autoimmune Diseases: A Bibliometric Analysis | 1 | B |
| Precision medicine | 213 | Hui Zhang | Multi-omics and human genetics implicate an NUDC-anchored n-6-PUFA-urate axis linking habitual tea intake to lower serum urate and gout risk | 1 | B |
| Rehabilitation for rheumatic diseases | 214 | Kanika Markan | Case Study: High-Intensity Physiotherapy Rehabilitation in Systemic Sclerosis–Myositis Overlap Syndrome | 1 | B |
| Rehabilitation for rheumatic diseases | 215 | Khilola Mirakhmedova | Effectiveness of hydrogen sulfide balneotherapy in the rehabilitation of patients with rheumatoid arthritis | 2 | C |
| Rehabilitation for rheumatic diseases | 216 | Masakazu Shimizu | Association of Foot Deformity and Functional Impairment with Callus Formation in Rheumatoid Arthritis | 2 | C |
| Rehabilitation for rheumatic diseases | 217 | Wenyu Xu | Family Caregiving Support as a Marker of Functional and Rehabilitation Needs in Rheumatic Diseases | 2 | C |
| Rheumatoid arthritis anti-TNF therapy | 218 | Jung-yoon Choe | Patient-Reported Outcomes and Clinical Remission with SB5 in Rheumatoid Arthritis and Ankylosing Spondylitis: Interim Results from the PRO-SIMILAR Study | 2 | C |
| Rheumatoid arthritis anti-TNF therapy | 219 | Jung-yoon Choe | Real-world Safety and effectiveness of SB5 (adalimumab biosimilar) in South Korea: A real-world Post-Marketing Surveillance data | 2 | C |
| Rheumatoid arthritis anti-TNF therapy | 220 | Yuko Kaneko | Relevant factors for successful dose reduction of a TNF blocker or methotrexate in rheumatoid arthritis from the randomised SORAIRO trial | 2 | C |
| Rheumatoid arthritis anti-TNF therapy | 221 | Sang Hoon Lee | Treatment Retention and Disease Activity of Subcutaneous Infliximab in Rheumatoid Arthritis and Ankylosing Spondylitis: A Korean Prospective Multicenter Cohort Study | 2 | C |
| Rheumatoid arthritis anti-TNF therapy | 222 | Hong Ki Min | Effect of methotrexate discontinuation on immunogenicity of recombinant zoster vaccine in patients with rheumatoid arthritis | 2 | C |
| Rheumatoid arthritis anti-TNF therapy | 223 | Melih Pamukcu | Anti-TNF Therapy Is Associated With Changes in Ventricular Repolarization Parameters in Rheumatoid Arthritis | 2 | C |
| Rheumatoid arthritis anti-TNF therapy | 224 | Haili Shen | H3K18 lactylation regulates AKR1C2 expression and contributes to the mechanisms of drug resistance in difficult-to-treat rheumatoid arthritis | 2 | C |
| Rheumatoid arthritis anti-TNF therapy | 225 | Haili Shen | Mesenchymal stem cell transplantation improves the treatment of refractory rheumatoid arthritis that is resistant to TNFi | 2 | C |
| Rheumatoid arthritis anti-TNF therapy | 226 | Tasuku Togashi | Real-World Comparison of Ozoralizumab, Certolizumab Pegol, and Other TNF Inhibitors : the ANSWER Cohort Study | 2 | C |
| Rheumatoid arthritis anti-TNF therapy | 227 | Ryu Watanabe | Efficacy of ozoralizumab irrespective of baseline IL-6/CRP levels in patients with RA: A post hoc analysis of the OHZORA/NATSUZORA trials | 2 | C |
| Rheumatoid arthritis bDMARDs | 228 | Soo Min Ahn | Clinical–Ultrasonographic Discordance in Rheumatoid Arthritis Across Biologic and Targeted Synthetic DMARDs | 2 | C |
| Rheumatoid arthritis bDMARDs | 229 | Dian Patrica Amri | Utilization Patterns of Biologic Disease-Modifying Anti-Rheumatic Drugs in Children : A Descriptive Study From a Tertiary Hospital in Indonesia | 2 | C |
| Rheumatoid arthritis bDMARDs | 230 | Anastasia Bobkova | Predictors of Rituximab Effectiveness in Rheumatoid Arthritis After Switching bDMARDs or JAKi | 2 | C |
| Rheumatoid arthritis bDMARDs | 231 | Anastasia Bobkova | Type I IFN Score and Inflammatory Activity in RA During bDMARD or JAKi Switching | 2 | C |
| Rheumatoid arthritis bDMARDs | 232 | Maria Borisova | Assessment of the effectiveness of abatacept therapy using the RAPID3 index. | 2 | C |
| Rheumatoid arthritis bDMARDs | 233 | Maria Borisova | The influence of inhibitor the co‐stimulation of T cells on functional status and radiographic progression in patients with rheumatoid arthritis | 2 | C |
| Rheumatoid arthritis bDMARDs | 234 | Sung Hae Chang | Clinical and Functional Outcomes of b/tsDMARD Switching in Older Rheumatoid Arthritis Patients: A Target Trial Framework–Informed KOBIO Study | 2 | C |
| Rheumatoid arthritis bDMARDs | 235 | Anastasia Demina | Flexible Intravenous and Subcutaneous Levilimab Dosing in Active Rheumatoid Arthritis: Results from the Phase III LUNAR Trial | 2 | C |
| Rheumatoid arthritis bDMARDs | 236 | Alina Fakhar | Health Disparities in Accessing Treatment by Rheumatoid Arthritis Patients in Pakistan | 2 | C |
| Rheumatoid arthritis bDMARDs | 237 | Gulshat Fathullina | Prognostic predictors of achieving remission of rheumatoid arthritis in patients on levilimab therapy in real clinical practice | 2 | C |
| Rheumatoid arthritis bDMARDs | 238 | Rasya Hapsari Danardhono | Bibliometric Mapping of Rheumatoid Arthritis Management Research in the Era of Biologics | 2 | C |
| Rheumatoid arthritis bDMARDs | 239 | Young Bin Joo | Real-world impact of biologic and targeted synthetic DMARDs on mortality in rheumatoid arthritis-associated interstitial lung disease | 2 | C |
| Rheumatoid arthritis bDMARDs | 240 | Ju-Yang Jung | Persistence by routes of biologic therapy and treatment sequencing in biologic-naïve patients with rheumatoid arthritis: a nationwide Korean claims study | 2 | C |
| Rheumatoid arthritis bDMARDs | 241 | Andrey Karateev | Correlation between disease activity and patient-reported outcomes in rheumatoid arthritis patients treated with olokizumab | 2 | C |
| Rheumatoid arthritis bDMARDs | 242 | Ji-Won Kim | Association Between DAS28-Guided Treatment De-escalation and Disease Flare in Rheumatoid Arthritis: A Nationwide Registry Study | 2 | C |
| Rheumatoid arthritis bDMARDs | 243 | Sungwon Ko | Treatment Patterns and Outcomes in Patients with Rheumatoid Arthritis after Discontinuation of Janus Kinase Inhibitors: A Real-World Cohort Study | 2 | C |
| Rheumatoid arthritis bDMARDs | 244 | Alexander Lila | Evaluation of the effect of therapy in patients with rheumatoid arthritis based on the immunophenotype of synovial tissue | 2 | C |
| Rheumatoid arthritis bDMARDs | 245 | Tatiana Lisitsyna | Cytokine Profile Dynamics in Rheumatoid Arthritis Patients During Olokizumab Therapy: a Single-Center Randomized Controlled Trial. | 2 | D |
| Rheumatoid arthritis bDMARDs | 246 | Tatiana Lisitsyna | Direct Inhibition of Interleukin-6 by Olokizumab is Effective Against Anemia in Patients With Rheumatoid Arthritis | 2 | D |
| Rheumatoid arthritis bDMARDs | 247 | Tatiana Lisitsyna | Dynamics of C-Reactive Protein, Calprotectin and Interleukin-6 Levels During 24-weeks Olokizumab Therapy in Patients with Rheumatoid Arthritis | 2 | D |
| Rheumatoid arthritis bDMARDs | 248 | Tatiana Lisitsyna | Psychopharmacotherapy of Depression Improves EULAR Treatment Response and Remission Rates in Rheumatoid Arthritis Patients Receiving Olokizumab | 2 | D |
| Rheumatoid arthritis bDMARDs | 249 | Galina Lukina | Efficacy of the IL-6 inhibitors Levilimab and Olokizumab in systemic vasculitis and connective tissue diseases in real clinical practice | 2 | D |
| Rheumatoid arthritis bDMARDs | 250 | Galina Lukina | IL-6 inhibitor Levilimab in comorbidity patients with RA | 2 | D |
| Rheumatoid arthritis bDMARDs | 251 | Khaiyom Mahmudzoda | Cardiovascular Comorbidity as Determinants of Patient-Reported Outcomes in Rheumatoid Arthritis | 2 | D |
| Rheumatoid arthritis bDMARDs | 252 | Aleksandra Makevnina | Real‑World Efficacy of Olokizumab after Switching from Targeted Therapy in Rheumatoid Arthritis: Cohort Study from the Moscow Region | 2 | D |
| Rheumatoid arthritis bDMARDs | 253 | Evgeni Melnikov | Practical aspects of levilimab use in comorbid patients with rheumatoid arthritis: data from the bDMARDs therapy center registry | 2 | D |
| Rheumatoid arthritis bDMARDs | 254 | Kiah Loon Ng | Real-World Rituximab Effectiveness and Safety in Southeast Asians - A Single Centre Experience in Malaysia | 2 | D |
| Rheumatoid arthritis bDMARDs | 255 | Oanh Nguyen | Sequential Triple Overlap of RA, Dermatomyositis, and Axial Spondyloarthritis: Rare IL-6-Driven Phenotype Responsive to Tocilizumab | 2 | D |
| Rheumatoid arthritis bDMARDs | 256 | Pavel Novikov | Pregnancy Outcomes and Disease Activity in Women with Rheumatoid Arthritis Treated with Olokizumab: A Descriptive Cohort Study | 2 | D |
| Rheumatoid arthritis bDMARDs | 257 | Yotaro Oki | Impact of n-3 Polyunsaturated Fatty Acid-Rich Fish Intake on Biomarker Changes Following Molecular-Targeted Therapy in Rheumatoid Arthritis | 2 | D |
| Rheumatoid arthritis bDMARDs | 258 | HeeJin Park | Biologic initiation and functional outcomes at follow-up in older rheumatoid arthritis patients: the KOBIO registry | 2 | D |
| Rheumatoid arthritis bDMARDs | 259 | Tatiana Popkova | Optimization of the Dosage of Biologics | 2 | D |
| Rheumatoid arthritis bDMARDs | 260 | Hashan Senarathna | A descriptive study on indication to commence, continue, change, or cease b inflammatory arthritides in Sri Lanka-dmards in chronic | 2 | D |
| Rheumatoid arthritis bDMARDs | 261 | Pavel Shesternya | Efficacy and Safety of Olokizumab Monotherapy in Patients with Rheumatoid Arthritis: Real-World Evidence | 2 | D |
| Rheumatoid arthritis bDMARDs | 262 | Pavel Shesternya | Pattern of Circulating MicroRNAs in Patients with Rheumatoid Arthritis Switching within the Class of IL-6 inhibitors. | 2 | D |
| Rheumatoid arthritis bDMARDs | 263 | Po-Cheng Shih | Comparative Safety of Abatacept Versus Tocilizumab in Patients With Rheumatoid Arthritis and Bronchiectasis: A Target Trial Emulation Study | 2 | D |
| Rheumatoid arthritis bDMARDs | 264 | Kenya Sugimoto | Early Rheumatoid Factor Decline Predicts Subsequent Clinical Remission in Rheumatoid Arthritis: The ANSWER Cohort | 2 | D |
| Rheumatoid arthritis bDMARDs | 265 | Shotaro Suzuki | Efficacy of rituximab in Japanese rheumatoid arthritis patients with inadequate response to bDMARDs or JAK inhibitors and/or with comorbidities | 2 | D |
| Rheumatoid arthritis bDMARDs | 266 | Thi Thanh Hang Vu | Adherence to biologic DMARD tapering strategies in patients with rheumatoid arthritis at the Center for Rheumatology at Bach Mai Hospital | 2 | D |
| Rheumatoid arthritis bDMARDs | 267 | Xuetong Wang | Efficacy Evaluation of CXCR4-Targeted Therapy in a Collagen-Induced Arthritis Rat Model: A Comparative Study with TNF-α Inhibitor | 2 | D |
| Rheumatoid arthritis bDMARDs | 268 | Alena.I. Zagrebneva | Efficacy of the Direct IL-6 Inhibitor Olokizumab in the Management of Rheumatoid Arthritis with Secondary Sjogren's Syndrome | 2 | D |
| Rheumatoid arthritis bDMARDs | 269 | Alena.I. Zagrebneva | Long-term Efficacy of Direct IL-6 Inhibitor Olokizumab in Rheumatoid Arthritis Therapy: Real-World Clinical Practice | 2 | D |
| Rheumatoid arthritis bDMARDs | 270 | Hao Zhang | Real-world Effectiveness and Safety of Ivarmacitinib in Patients with Active and Difficult-to-Treat Rheumatoid Arthritis: A Single-Center Retrospective Study | 2 | D |
| Rheumatoid arthritis clinical aspects and co-morbidity | 271 | Masahiro Horita | Reliability and validity of the Japanese version of Rheumatoid Arthritis Foot Disease Activity Index-5 | 2 | D |
| Rheumatoid arthritis clinical aspects and co-morbidity | 272 | Elena Myasoedova | Ten-Year Population Attributable Risk of Dementia in Rheumatoid Arthritis: Role of Cardiovascular Disease, Serostatus and Cumulative Inflammatory Burden | 2 | D |
| Rheumatoid arthritis clinical aspects and co-morbidity | 273 | Yejun Tan | Type 2 Diabetes Predicts Severe Infection and Hospitalization in Rheumatoid Arthritis: A Real-World Cohort Study | 2 | D |
| Rheumatoid arthritis csDMARDs | 274 | Soo-Kyung Cho | 2025 Korean Clinical Practice Guidelines for the Pharmacologic Treatment of Rheumatoid Arthritis | 2 | D |
| Rheumatoid arthritis csDMARDs | 275 | Uthpala Dissanayake | Real-World Management of Rheumatoid Arthritis in a Tertiary Hospital in Sri Lanka: Drugs, Delays and Practice Changes Following Structured Intervention | 2 | D |
| Rheumatoid arthritis csDMARDs | 276 | Jeong Eunji | Low Baseline HDL-Cholesterol and Early Treatment Patterns as Risk Factors for Interstitial Lung Disease in Rheumatoid Arthritis: CDM-Based Cohort Study | 2 | D |
| Rheumatoid arthritis csDMARDs | 277 | Toshihiro Matsui | Real-world Treatment Patterns of Rheumatoid Arthritis According to Methotrexate Use in the NinJa Registry | 2 | D |
| Rheumatoid arthritis csDMARDs | 278 | Binish Haseeb Mukry | Tolerability as a Key Determinant of Methotrexate Response in Rheumatoid Arthritis: A Real-World Cohort Study | 2 | D |
| Rheumatoid arthritis csDMARDs | 279 | Chun Ruh Ng | Effectiveness and Safety of Methotrexate Triple Vs Double Therapy in Rheumatoid Arthritis Treatment : A Retrospective Comparison | 2 | D |
| Rheumatoid arthritis csDMARDs | 280 | Eva Christina Schwaneck | From Tolerability to Strategy: How Subcutaneous Methotrexate Is Used Differently in Asia and Germany | 2 | D |
| Rheumatoid arthritis csDMARDs | 281 | Taskin Senturk | The effect of disease-modifying antirheumatic drugs on sleep and quality of life in older patients with rheumatoid arthritis | 2 | D |
| Rheumatoid arthritis csDMARDs | 282 | Yasumori Sobue | Methotrexate Use Is Associated With Recovery From Locomotive Syndrome in Rheumatoid Arthritis | 2 | D |
| Rheumatoid arthritis csDMARDs | 283 | Ramaswamy Subramanian | Hydroxychloroquine-induced cutaneous hyperpigmentation in a south Indian rheumatology cohort: prevalence, clinical spectrum, and associated factors | 2 | D |
| Rheumatoid arthritis csDMARDs | 284 | Takeshi Suga | Comparative Effectiveness of Subcutaneous and Oral Methotrexate as Initial Therapy for Rheumatoid Arthritis: A Two-Center Cohort Study | 2 | D |
| Rheumatoid arthritis non biological treatment | 285 | Zhengze Dai | Jianpi Jiangzhuo prescription alleviates uric acid nephropathy in rats via the TLR4/Myd88/NF-κB signaling pathway | 2 | D |
| Rheumatoid arthritis non biological treatment | 286 | Maheen Jamal | Outcome of Early Rheumatoid Arthritis Patients Taking Bioequivalent Amount of Oral Prednisolone Versus Intramuscular Methylprednisolone | 2 | D |
| Rheumatoid arthritis non biological treatment | 287 | Yi Wye Lai | Glucocorticoid Discontinuation Patterns in Patients with Newly Diagnosed Rheumatoid Arthritis in an Early Arthritis Clinic | 2 | D |
| Rheumatoid arthritis non biological treatment | 288 | Hongyan Qian | PDPN-Targeted Polypeptide Inhibitor for PET/CT Imaging and Therapy of Rheumatoid Arthritis | 2 | D |
| Rheumatoid arthritis non biological treatment | 289 | Evgenii Pletnev | Therapeutic Potential of Selective cfDNA/NETs Apheresis in Difficult-to-Treat Rheumatoid Arthritis | 2 | D |
| Rheumatoid arthritis non biological treatment | 290 | Haili Shen | Tetrandrine Reverses Methotrexate Resistance in Rheumatoid Arthritis Fibroblast-Like Synoviocytes by Downregulating MRP1 | 2 | D |
| Rheumatoid arthritis non biological treatment | 291 | Elena Taskina | Long-Term outcomes knee arthroscopic synovectomy in rheumatoid arthritis | 2 | D |
| Rheumatoid arthritis non biological treatment | 292 | Elena Taskina | Outcomes reverse shoulder arthroplasty with glenoid bone grafting: rheumatoid arthritis versus osteoarthritis | 2 | D |
| Rheumatoid arthritis non-TNF biological therapies | 293 | Soyoung Bang | Peripheral blood single-cell transcriptomics reveals predictive signatures of abatacept response in rheumatoid arthritis | 2 | D |
| Rheumatoid arthritis non-TNF biological therapies | 294 | Larisa Ivanova | Early clinical response as a predictor of sustained remission during levilimab therapy in patients with rheumatoid arthritis: 104-week data | 2 | D |
| Rheumatoid arthritis non-TNF biological therapies | 295 | Tatiana Popkova | Effect of IL-6 receptor inhibitor therapy on cardiovascular risk and structural changes in carotid arteries in patients with rheumatoid arthritis | 2 | D |
| Rheumatoid arthritis tsDMARDs | 296 | Hirotomo Asakura | MS4A4A on nonclassical monocyte predicts early remission with JAK inhibitors in rheumatoid arthritis. | 2 | D |
| Rheumatoid arthritis tsDMARDs | 297 | Masashi Aso | Treatment Strategies and Radiographic Outcomes in Early Rheumatoid Arthritis : A Decade of Experience from the Yonezawa Cohort | 2 | D |
| Rheumatoid arthritis tsDMARDs | 298 | Hirofumi Bekki | Janus Kinase Inhibitor withholding period for 24 hours: Perioperative Outcome After Orthopedic Surgeries in Patients with Rheumatoid Arthritis | 2 | D |
| Rheumatoid arthritis tsDMARDs | 299 | Poku Chen | Integrating Genetic Variants and Clinical Features via Machine Learning for Predicting Herpes Zoster in JAKi-Treated Rheumatoid Arthritis Patients | 2 | D |
| Rheumatoid arthritis tsDMARDs | 300 | Soo-Kyung Cho | Long-term remission and safety of JAKis versus biologic DMARDs in Korean patients with RA: a national multicenter real-world extension study | 2 | D |
| Rheumatoid arthritis tsDMARDs | 301 | Soo-Kyung Cho | Treatment switching patterns and long-term persistence in patients with rheumatoid arthritis initiating targeted therapy: national multicenter study | 2 | D |
| Rheumatoid arthritis tsDMARDs | 302 | Ryuhei Ishihara | Distinct transcriptomic signatures of humoral and cellular responses to recombinant zoster vaccine in rheumatoid arthritis: the End Zoster-J study | 2 | D |
| Rheumatoid arthritis tsDMARDs | 303 | Joonyoung Jang | Genetic evidence on the efficacy and safety of JAK inhibitors in rheumatoid arthritis | 2 | D |
| Rheumatoid arthritis tsDMARDs | 304 | YoungEun Kim | Effect of Janus Kinase Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients with Osteoporosis | 2 | D |
| Rheumatoid arthritis tsDMARDs | 305 | Oh Chan Kwon | Cardiovascular risk associated with first-line JAK inhibitors versus TNF inhibitors in patients with RA: a nationwide cohort study | 2 | D |
| Rheumatoid arthritis tsDMARDs | 306 | Trang Nguyen Thi Ha | Resolution of subchondral osteolytic lesions with tofacitinib in refractory oligoarticular juvenile idiopathic arthritis | 2 | D |
| Rheumatoid arthritis tsDMARDs | 308 | Sho Sendo | Dissociation between rheumatoid factor reduction and clinical response with tsDMARDs versus bDMARDs in rheumatoid arthritis: the ANSWER cohort | 2 | D |
| Rheumatoid arthritis tsDMARDs | 309 | Md Abu Shahin | Baricitinib, Methotrexate as Monotherapy or Combination in the Treatment of Rheumatoid Arthritis - An Open Label Randomized Clinical Trial | 2 | D |
| Rheumatoid arthritis tsDMARDs | 310 | Sushant Shinde | Tofacitinib in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review of Efficacy and Safety | 2 | D |
| Rheumatoid arthritis tsDMARDs | 311 | Ryu Watanabe | Immunogenicity and Safety of Recombinant Zoster Vaccine in Japanese Patients with RA Receiving Upadacitinib: The End Zoster-J Study | 2 | E |
| Rheumatoid arthritis tsDMARDs | 312 | Saira Yasmin | Rapid Remission in Rheumatoid Arthritis: A Head-to-Head Comparison of Tofacitinib and Upadacitinib | 2 | E |
| Rheumatoid arthritis tsDMARDs | 313 | Dr Alam Zeb | Efficacy, tolerability, and adverse events of tofacitinib in rheumatoid arthritis: a real-world study at Khyber Teaching Hospital, Peshawar, Pakistan | 2 | E |
| Scleroderma, myositis and related syndromes | 314 | Askat Abdykerimov | Demographic and clinical-immunological features of systemic sclerosis in patients of the Kyrgyz population | 2 | E |
| Scleroderma, myositis and related syndromes | 315 | Aashish Agrawal | Long term progression of Systemic Sclerosis and Mixed connective tissue disease associated Interstitial Lung Disease | 2 | E |
| Scleroderma, myositis and related syndromes | 316 | Aashish Agrawal | Serial CA 15-3 and KL-6 correlate with pulmonary function, HRCT and disease activity in patients with systemic sclerosis–associated ILD | 2 | E |
| Scleroderma, myositis and related syndromes | 317 | Hajar Al Majarfi | Successful management of clinically amyopathic dermatomyositis (CADM) due to MDA-5 antibodies: Case report and literature review | 2 | E |
| Scleroderma, myositis and related syndromes | 318 | Daisuke Baba | Short-term Outcomes of Cyclophosphamide and Nintedanib Combination Therapy in Systemic Sclerosis–Associated Interstitial Lung Disease | 2 | E |
| Scleroderma, myositis and related syndromes | 319 | Natalia Babadaeva | Primary cardiac involvement in systemic sclerosis: a focus on MRI | 2 | E |
| Scleroderma, myositis and related syndromes | 320 | Hakan Babaoglu | FIB-4 Score in Systemic Sclerosis: Age-Dependent Variation and Exploratory Associations with Disease Subtypes and Treatment | 2 | E |
| Scleroderma, myositis and related syndromes | 321 | Saltanat Bakirova | Cellular Technologies in the Treatment of Systemic Sclerosis: Morphological Evaluation of the Efficacy of Mesenchymal Stem Cells | 2 | E |
| Scleroderma, myositis and related syndromes | 322 | Sandeep Balakrishnan | Cancer-Associated Myositis in India: Aggressive Disease Course and Distinct Malignancy Spectrum | 2 | E |
| Scleroderma, myositis and related syndromes | 323 | Choon Guan Chua | Case series: Clinical characteristics of immune-mediated necrotising myopathies in aSoutheast Asian population | 2 | E |
| Scleroderma, myositis and related syndromes | 324 | Gulshat Dalibayeva | Overlap Syndrome: Coexistence of Rheumatoid Arthritis and Systemic Sclerosis (A Clinical Case) | 2 | E |
| Scleroderma, myositis and related syndromes | 325 | Yunus Emre Dalkılıç | Sex-Related Differences in Clinical Phenotype and Treatment Patterns in Systemic Sclerosis | 2 | E |
| Scleroderma, myositis and related syndromes | 326 | Jessica Day | Clinical Trial Protocols in patients with Inclusion Body Myositis: A Systematic Literature Review | 2 | E |
| Scleroderma, myositis and related syndromes | 327 | Jessica Day | Enhancing Diagnostic and Care Pathways: Insights from a Rheumatology- Neurology Neuromuscular Collaborative Service | 2 | E |
| Scleroderma, myositis and related syndromes | 328 | Sumartini Dewi | Serum ca 15-3 as a new biomarker to differentiate the severity and type of interstitial lung disease in systemic sclerosis | 2 | E |
| Scleroderma, myositis and related syndromes | 329 | Shamas U Din | Dermatoscopic Assessment of Nail Fold Capillary Patterns in Different Autoimmune Rheumatic Diseases | 2 | E |
| Scleroderma, myositis and related syndromes | 330 | My Doan Ai Thao | Lower Motor Neuron Disease Mimicking Polymyositis in a Young Woman With Myositis - Specific Antibodies: A Case Report | 2 | E |
| Scleroderma, myositis and related syndromes | 331 | Mehmet Tuncay Duruoz | Serum Uric Acid as a Potential Marker of Microvascular Damage in Systemic Sclerosis: Association with Nailfold Capillaroscopy Patterns | 2 | E |
| Scleroderma, myositis and related syndromes | 332 | Asena Eken | Clinical and Laboratory Factors Associated with Nutritional Risk in Systemic Sclerosis | 2 | E |
| Scleroderma, myositis and related syndromes | 333 | Abdulsamet Erden | Screening Rates and Predictive Factors of Osteoporosis in a Turkish Systemic Sclerosis Cohort | 2 | E |
| Scleroderma, myositis and related syndromes | 334 | Abdulsamet Erden | The Prevalence, Etiology, and Impact of Anemia on Disease Progression in Systemic Sclerosis Patients: A Retrospective Cohort Study | 2 | E |
| Scleroderma, myositis and related syndromes | 335 | Delia Fernandez Lozano | Prevalence and Clinical Associations of Rectal Prolapse in Patients with Systemic Sclerosis | 2 | E |
| Scleroderma, myositis and related syndromes | 336 | Chingching Foocharoen | Diagnostic accuracy and referral delays as prognostic factors for clinical outcomes among scleroderma referred to tertiary care: Nationwide Database Analysis | 2 | E |
| Scleroderma, myositis and related syndromes | 337 | Jie Gao | Efficacy and safety of allogeneic CD19 CAR NK cell therapy in systemic sclerosis | 2 | E |
| Scleroderma, myositis and related syndromes | 338 | Liudmila Garzanova | Consistent Efficacy of Divozilimab, an Anti-CD20 Therapy, Across Patient Subgroups in Systemic Sclerosis: Post-hoc Analysis from the LIBERIUS Study | 2 | E |
| Scleroderma, myositis and related syndromes | 339 | Liudmila Garzanova | Dynamics of MCP-1 during of anti-B-cell therapy in patients with systemic scleroderma and interstitial lung disease | 2 | E |
| Scleroderma, myositis and related syndromes | 340 | Liudmila Garzanova | The value KL-6 serum level in assessing the progression of the interstitial lung disease in systemic sclerosis during active therapy | 2 | E |
| Scleroderma, myositis and related syndromes | 341 | Liudmila Garzanova | TNF-alpha is a promising target for the treatment of endothelial dysfunction in systemic sclerosis | 2 | E |
| Scleroderma, myositis and related syndromes | 342 | Samuel Good | The Psychosocial Burden of Systemic Sclerosis-Associated Gastrointestinal Disease: A Qualitative Grounded Theory Study | 2 | E |
| Scleroderma, myositis and related syndromes | 343 | Thineshan Gopalakrishnan | Life-Threatening Hypokalemia Revealing Dermatomyositis with Distal Renal Tubular Acidosis: A Rare Overlap | 2 | E |
| Scleroderma, myositis and related syndromes | 344 | Thineshan Gopalakrishnan | Severe pulmonary arterial hypertension revealing systemic sclerosis sine scleroderma in an adolescent | 2 | E |
| Scleroderma, myositis and related syndromes | 345 | Rasya Hapsari Danardhono | Clinical Outcomes of Tocilizumab Therapy in Systemic Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | 2 | E |
| Scleroderma, myositis and related syndromes | 346 | Tsz Chung Ho | Anti-cN1A in myositis specific antibody panel is non-specific for inclusion body myositis | 2 | E |
| Scleroderma, myositis and related syndromes | 347 | Faith Hong | Increased risk of Multi-Organ Involvement in Asians Patients with Systemic Sclerosis (SSc)- Systemic Lupus Erythematous (SLE) Overlap Syndrome | 2 | E |
| Scleroderma, myositis and related syndromes | 348 | Iuliia Ivanova | Pneumomediastinum is a rare complication of dermatomyositis: a clinical case | 2 | E |
| Scleroderma, myositis and related syndromes | 349 | Sankar Jayaprakash | Retrospective study of clinical, serological and treatment profile of male systemic sclerosis patients from India | 2 | E |
| Scleroderma, myositis and related syndromes | 350 | Nuttathum Jirakiat | Study of Heavy Metal and Metalloid Levels in Systemic Sclerosis Patients | 2 | E |
| Scleroderma, myositis and related syndromes | 351 | Jae-Bum Jun | Seasonal Variation in Public Interest in Raynaud's Phenomenon: A Search Trend Analysis in South Korea and a Cross-National Comparison | 2 | E |
| Scleroderma, myositis and related syndromes | 352 | Zhuldyz Kali | Clinical case of systemic sclerosis with high disease activity, interstitial lung disease, Sjögren’s syndrome, and chronic Herpes Zoster infection. | 2 | E |
| Scleroderma, myositis and related syndromes | 353 | Shizuko Katahira | Practical Interdepartmental Collaboration for Early Detection of Pulmonary Hypertension in Patients with Connective Tissue Diseases | 2 | E |
| Scleroderma, myositis and related syndromes | 354 | Shefali Khanna | A Randomized Controlled Trial Comparing the Efficacy and Safety of Baricitinib Versus Mycophenolate Mofetil in Systemic Sclerosis | 2 | E |
| Scleroderma, myositis and related syndromes | 355 | Seon Uk Kim | Characterizing the Signaling Patterns Myonuclei and Their Contribution to the Pathogenic Microenvironment in Dermatomyositis | 2 | E |
| Scleroderma, myositis and related syndromes | 356 | Ee Tzun Koh | Bilateral anterior uveitis and retinal vasculitis in a patient with sine scleroderma – a case report | 3 | E |
| Scleroderma, myositis and related syndromes | 357 | Yasushi Kondo | Predictors of Relapse Following Immunosuppressive Therapy in Non-Systemic Sclerosis Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: The Keio-CTD-PH Cohort Study | 3 | F |
| Scleroderma, myositis and related syndromes | 358 | Anastasia Konstantinova | Analysis of IP-10 (CXCL10) levels in patients with systemic sclerosis | 3 | F |
| Scleroderma, myositis and related syndromes | 359 | Mikhail Kostik | Efficacy and Safety of Divozilimab in Adolescents with Juvenile Systemic Sclerosis: Results after 48 Weeks of Therapy in LIBERIUS Study | 3 | F |
| Scleroderma, myositis and related syndromes | 360 | Takuya Kotani | Functional priming enhances tissue accumulation and antifibrotic efficacy of adipose-derived mesenchymal stem cells in systemic sclerosis–associated interstitial lung disease | 3 | F |
| Scleroderma, myositis and related syndromes | 361 | Irina Kovrigina | Orofacial pain in patients with systemic scleroderma: clinical and laboratory characteristics | 3 | F |
| Scleroderma, myositis and related syndromes | 362 | Katsuhide Kusaka | Haemodynamic prognosis of exercise-induced pulmonary hypertension and early pulmonary arterial hypertension in systemic sclerosis | 3 | F |
| Scleroderma, myositis and related syndromes | 363 | Kyung-Ann Lee | Clinical Course and Survival Outcomes in Anti-MDA5–Associated Interstitial Lung Disease: A Two-Center Retrospective Study | 3 | F |
| Scleroderma, myositis and related syndromes | 364 | Kyung-Ann Lee | Serum CXCL-10 as a Predictor of Progressive Pulmonary Fibrosis in SSc-ILD: A Prospective Observational Study Comparing Serum and Salivary Biomarkers | 3 | F |
| Scleroderma, myositis and related syndromes | 365 | Xiaomin Li | Efficacy of Umbilical Cord-Derived Mesenchymal Stromal Cells in anti-MDA5 Antibody-Positive Dermatomyositis with Interstitial Lung Diseases: A Real-World Retrospective Cohort Study | 3 | F |
| Scleroderma, myositis and related syndromes | 366 | Tao Liu | Title: Dermatomyositis with Digital Gangrene: clinical clues and poor short-term prognosis | 3 | F |
| Scleroderma, myositis and related syndromes | 367 | Worawit Louthrenoo | Prevalence and associated factors of sarcopenia among patients with systemic sclerosis: A cross-sectional study | 3 | F |
| Scleroderma, myositis and related syndromes | 368 | Andrea Low | Baseline Characteristics of the APLAR Systemic Sclerosis Incident Cohort (APSSIC) | 3 | F |
| Scleroderma, myositis and related syndromes | 369 | Kanika Markan | HAQ-DI Disability Profile in Systemic Sclerosis With and Without Interstitial Lung Disease | 3 | F |
| Scleroderma, myositis and related syndromes | 370 | Mohamad Fadhli Bin Masri | Upfront use of combination therapy in treatment of anti-MDA5 positive dermatomyositis associated interstitial lung disease improves mortality and clinical outcomes. | 3 | F |
| Scleroderma, myositis and related syndromes | 371 | Jithin Mathew | Air Everywhere But the Lungs: A Radiographic Tetrad of MDA5-Dermatomyositis with Rapidly Progressive Interstitial Lung Disease | 3 | F |
| Scleroderma, myositis and related syndromes | 372 | Ekaterina Mikheeva | Emphysema mimicking interstitial lung disease: a case series | 3 | F |
| Scleroderma, myositis and related syndromes | 373 | Hong Ki Min | Risk of Alzheimer’s dementia in patients with systemic sclerosis: data from nation-wide health insurance claim data | 3 | F |
| Scleroderma, myositis and related syndromes | 374 | Lekshmi Minikumari Rahulan | Patient-Physician Discordance in Idiopathic Inflammatory Myopathies: A Longitudinal Analysis of Links to Disease Activity and Damage | 3 | F |
| Scleroderma, myositis and related syndromes | 375 | Dezza Montejo | Dermatomyositis as paraneoplastic herald for high grade b cell lymphoma in a 63-year old female | 3 | F |
| Scleroderma, myositis and related syndromes | 376 | Jae Hyun Moon | Untargeted Metabolomic Profiling Identified the Kynurenine Pathway as a Pathophysiological Indicator in Idiopathic Inflammatory Myopathy | 3 | F |
| Scleroderma, myositis and related syndromes | 377 | Ludovic Musgrave | An Atypical Presentation of Systemic Sclerosis with Monoarticular Acro-osteolysis | 3 | F |
| Scleroderma, myositis and related syndromes | 378 | Zinaida Mutovina | IFN-I genes signature as a stratification biomarker in Systemic Sclerosis | 3 | F |
| Scleroderma, myositis and related syndromes | 379 | Pawikorn Nampisai | Longitudinal follow-up of anti-topoisomerase I antibody level and skin outcomes in Thai systemic sclerosis | 3 | F |
| Scleroderma, myositis and related syndromes | 380 | Phuc Nguyen Hoang | From Autoantibodies to Outcomes: Characterizing Idiopathic Inflammatory Myopathies with links to Interstitial Lung Disease and Malignancies in a Vietnamese Cohort | 3 | F |
| Scleroderma, myositis and related syndromes | 381 | Phuong Ninh Cong | Renal Manifestations and Their Association with Anti-RNA Polymerase III Antibodies in Vietnamese Patients with Systemic Sclerosis | 3 | F |
| Scleroderma, myositis and related syndromes | 382 | Shahleni Paramasivam | When the voice breaks: MDA-5 Dermatomyositis with Ulcerative Laryngitis and Progressive Interstitial Lung Disease. | 3 | F |
| Scleroderma, myositis and related syndromes | 383 | Hee Won Park | Clinical Characteristics and Factors Associated with Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis-associated Interstitial Lung Disease | 3 | F |
| Scleroderma, myositis and related syndromes | 384 | Trang Pham | Assessment of gastrointestinal involvement in patients with systemic sclerosis using the UCLA GIT 2.0 questionnaire and related factors | 3 | F |
| Scleroderma, myositis and related syndromes | 385 | Thayalan Ponniah | Long term outcomes in systemic sclerosis-associated interstitial lung disease (ssc-ild) in a multicenter cohort in Malaysia | 3 | F |
| Scleroderma, myositis and related syndromes | 386 | Tatiana Popkova | Diagnostic and prognostic significance of pulmonary functional parameters in systemic sclerosis-associated lung disease | 3 | F |
| Scleroderma, myositis and related syndromes | 387 | Tatiana Popkova | The path to the diagnosis of pulmonary arterial hypertension through the clinical picture of systemic sclerosis | 3 | F |
| Scleroderma, myositis and related syndromes | 388 | Jasmin Raja | Clinical and serological profiles of idiopathic inflammatory myopathies in a multi-ethnic Asian cohort from a single tertiary centre | 3 | F |
| Scleroderma, myositis and related syndromes | 389 | Jul Necholie Rosales | Scleroderma Mimicry: Lupus Nephritis unmasked in Renal Crisis | 3 | F |
| Scleroderma, myositis and related syndromes | 390 | Laura Ross | Functional Index 3 in Systemic Sclerosis Associated Myopathy: Screening Performance and Association With Myopathic Features | 3 | F |
| Scleroderma, myositis and related syndromes | 391 | Jed Salazar | Attack of the Statins: A Case of Proximal Muscle Weakness | 3 | F |
| Scleroderma, myositis and related syndromes | 392 | Sushant Shinde | Anti Th/To Positive Interstitial Lung Disease without Scleroderma Phenotype: A Case Series from India | 3 | F |
| Scleroderma, myositis and related syndromes | 393 | Megha Sridhar | Steroid-responsive skin thickening beyond Scleroderma: A case of Eosinophilic Fascitiis | 3 | F |
| Scleroderma, myositis and related syndromes | 394 | Tomohiro Sugimoto | Anti-ARS Autoantibody Titres as a Predictor of Flare in ASyS-associated Interstitial Lung Disease | 3 | F |
| Scleroderma, myositis and related syndromes | 395 | Naonobu Sugiyama | Safety and Efficacy of Zola-cel, a Chimeric Antigen Receptor T Cell Therapy, in Systemic Sclerosis: Findings From the Breakfree-1 Trial | 3 | F |
| Scleroderma, myositis and related syndromes | 396 | Irene Tan | Association of GLP-1 Receptor Agonists with Pulmonary Hypertension, Interstitial Lung Diseases, and Major Cardiovascular Events in Systemic Sclerosis | 3 | F |
| Scleroderma, myositis and related syndromes | 397 | Jiekai Tan | Discordance Between Line Blot and Immunoprecipitation in the Detection of Myositis Antibodies in Idiopathic Inflammatory Myopathies | 3 | F |
| Scleroderma, myositis and related syndromes | 398 | Byorn Tan Wei Liang | A Double Autoimmune Hit: Development of ANCA-associated Glomerulonephritis in a Patient with Systemic Sclerosis | 3 | F |
| Scleroderma, myositis and related syndromes | 399 | Iris Tang | Universal versus risk-factor based screening for interstitial lung disease in idiopathic inflammatory myopathy | 3 | F |
| Scleroderma, myositis and related syndromes | 400 | Tobias Teo | Mapping Mortality Predictors and Prognostic Models in Anti-MDA5 Dermatomyositis Associated RP-ILD: A Scoping Review | 3 | F |
| Scleroderma, myositis and related syndromes | 401 | Natsuka Umezawa | A novel therapeutic strategy targeting RasGRP4 in idiopathic inflammatory myopathies. | 3 | F |
| Scleroderma, myositis and related syndromes | 402 | Anggarda Kristianti Utomo | A 43-Year-Old Woman with Anti-Ku Positive Overlap Syndrome of Systemic Sclerosis and Sjögren Disease | 3 | F |
| Scleroderma, myositis and related syndromes | 403 | Kiran Wakade | Tumor Immunity Unmasked: Anti-TIF1-γ Dermatomyositis following Chemotherapy for Ovarian Carcinoma | 3 | F |
| Scleroderma, myositis and related syndromes | 404 | Ruolin Wang | Analysis of clinical characteristics and risk factors of progressive pulmonary fibrosis associated with systemic sclerosis patients | 3 | F |
| Scleroderma, myositis and related syndromes | 405 | Pingcuo Wangzha | Comprehensive Profiling of Autoantibody Spectrum and Lymphocyte Subsets in Systemic Sclerosis: A Large-Scale Real-World Study | 3 | F |
| Scleroderma, myositis and related syndromes | 406 | Yue Xie | Clinical Characteristics and Development of a Risk Prediction Model for Cytomegalovirus Infection/Reactivation in Patients with Idiopathic Inflammatory Myopathies | 3 | F |
| Scleroderma, myositis and related syndromes | 407 | Neli Yovkova | Nailfold videocapillaroscopy in the diagnostic algorithm of connective tissue diseases presenting with Raynaud’s phenomenon as a first cilnical manifestation. | 3 | F |
| Scleroderma, myositis and related syndromes | 408 | Geraldine Zamora | Characterizing Cutaneous Manifestations of Systemic Autoimmune Rheumatologic Diseases in Filipino Skin | 3 | F |
| Scleroderma, myositis and related syndromes | 409 | Anel Zhumabek | Severe Antisynthetase Syndrome with Interstitial Lung Disease in Combination with Advanced Rheumatoid Arthritis | 3 | F |
| Soft tissue rheumatism | 410 | I-shu Chen | Real-world Experience of Sildenafil in Connective Tissue Disease-associated Pulmonary Arterial Hypertension at a tertiary referral system in Taiwan | 3 | F |
| Soft tissue rheumatism | 411 | Anh Ngo | Subacromial Hyaluronic Acid Injection versus Extracorporeal Shockwave Therapy for Rotator Cuff Tendinopathy with Absent or Minimal Calcification: A Prospective Study | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 412 | Roger Abramino Levy | Biologic Therapies for Disease Modification in Systemic Lupus Erythematosus (SLE): A Systematic Review of Belimumab, Telitacicept, and Anifrolumab | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 413 | Damir Aliev | Successful treatment of refractory sle in a patient with overexpression of interferon signature genes | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 414 | Ning An | Renal protective effect and mechanism of regulating M2 pyruvate kinase(PKM2) in lupus nephritis mice | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 415 | Azmad Kareem Bin Anwardeen | Serology predicts treatment escalation after rituximab in systemic lupus erythematosus: a real-world cohort | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 416 | Boonnum Banda | Assessing the role of AI-driven chatbots in enhancing patient education and self management in systemic lupus erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 417 | Linh Bui-Thi-Khanh | Belimumab for Systemic Lupus Erythematosus: Early Insights from a Single-Center Vietnamese Cohort | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 418 | Winter Cervantes | Outcomes of mppt among Filipino adult patients with sle admitted at Valenzuela medical center from 2019–2025:a descriptive cross-sectional retrospective study | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 419 | Ding Ping Chen | Investigation of the impact of genetic polymorphisms in immunosuppressant metabolism on therapeutic response and underlying mechanisms in systemic lupus erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 420 | Vivian Man Yui Choi | Effectiveness and safety of belimumab treatment in SLE patients in Hong Kong - a real-world study | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 421 | Jan Davidson-Moncada | CTA313, CD19/BCMA dual targeted allo-CAR-T cell, Induces Deep B-Cell depletion and Durable Remission in Lupus Nephritis | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 422 | Chung Heng Hsiao | Efficacy and Safety of Obinutuzumab in Patients with Lupus Nephritis: A Single-Center Real-World Experience | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 423 | Helena Jang | Concurrent Rituximab and Anifrolumab Therapy in Refractory Multisystem Systemic Lupus Erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 424 | Hyerim Jin | Disease Burden and Treatment Preferences Evaluation in Systemic Lupus Erythematosus: Results from a Global Real-World Survey | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 425 | Meng Jin | Jiawei Sini San Alleviates High-Dose Glucocorticoid-Induced Mood Abnormalities in SLE with Restoration of Endothelial KLF4 and BBB Integrity | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 426 | Masao Katsushima | Differential Glucocorticoid Tapering Rates After Biologic Initiation in Systemic Lupus Erythematosus: The ANSWER-SLE Cohort | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 427 | Zumrad Khamroeva | Clinical and Cardiovascular Profile of Systemic Lupus Erythematosus Patients in Tajikistan | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 428 | YoungEun Kim | Real-World Outcomes of Belimumab or Calcineurin Inhibitor Add-On Therapy to Mycophenolate in Lupus Nephritis | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 429 | Ruihan Li | Efficacy and Safety of CAR-T Cell Therapy for the Treatment of Autoimmune Diseases: A Systematic Review and Meta-Analysis | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 430 | Xing Liu | Application of a Human Immune System-Reconstituted Mouse Model of Lupus in Evaluating the Efficacy of B Cell-Targeting Therapies | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 431 | Thomas Mandl | Fatigue, Pain, Stiffness and Quality of Life Improvements in Systemic Lupus Erythematosus with Dapirolizumab Pegol: 48-Week Phase 3 Trial Results | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 432 | Jithin Mathew | The Vanishing Lung: Two Young SLE Patients Rescued by Rituximab | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 433 | Satsuki Matsunaga | Efficacy of Anifrolumab in SLE patients who have not achieved LLDAS and factors associated with treatment response:Results from LOOPS Study | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 434 | Chandrashekara Mn | In-hospital mortality in systemic lupus erythematosus patients with and without acute myocardial dysfunction: a retrospective comparative study | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 435 | Quynh Nguyen | Cyclophosphamide: A Potent Immunosuppressive Treatment for Aggressive Interstitial Lung Disease in a Child with Systemic Lupus Erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 436 | Clarissa Oktavia | Adjunctive Acupuncture in Systemic Lupus Erythematosus: A Scoping Review of Evidence and Research Gaps | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 437 | Ping Seung Ong | Pulling the doom trigger – A Case of Catastrophic Antiphospholipid Syndrome In Systemic Lupus Erythematosus with recent initiation of Elthrombopag. | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 438 | Jingyi Peng | Complete Response at Three Months as an Independent Predictor of Renal Prognosis in Lupus Nephritis | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 439 | Evgenii Pletnev | Anifrolumab in patients with systemic lupus erythematosus (Results of a 6-month study) | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 440 | Evgenii Pletnev | Quality of life factors in patients with systemic lupus erythematosus in Lupus Patients from Russian Federation , Kirghizstan and Kazakhstan | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 441 | Evgenii Pletnev | Therapeutic potential of selective cfDNA/NETs apheresis in severe systemic lupus erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 442 | Prayuda Prayuda | Mesenchymal Stem Cells Comprehensively Attenuate Renal Injury in Lupus Nephritis: A Systematic Review and Meta-Analysis of Preclinical Evidence | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 443 | Hidenori Sakai | Glucocorticoid-sparing effects of belimumab over three years in systemic lupus erythematosus with active kidney involvement from the LOOPS registry | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 444 | Joydeep Samanta | Short-Term Renal Outcomes and Predictors of Response in Lupus Nephritis: An Ambispective Real-World Cohort from Central India | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 445 | Carlos Santini | Mycophenolate induced acute inflammatory syndrome | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 446 | Phongpon Sumangin | Optimal Hydroxychloroquine Dose Reduction in Patients with Quiescent Systemic Lupus Erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 447 | Hiroshi Takei | The impact of hydroxychloroquine use on the immune system in clinically quiescent patients with systemic lupus erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 448 | Lay Kim Tan | Mapping of MHC Regions Reveals a Genetic Architecture for Lupus Nephritis Distinct from SLE Susceptibility in Malay patients | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 449 | Yejun Tan | Impact of Preconception Remission with Low-Dose Prednisone on SLE Pregnancy Outcomes: A Target Trial Emulation | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 450 | Yoshiya Tanaka | Litifilimab in Systemic Lupus Erythematosus: TOPAZ Phase 3 Program Study Design and Baseline Characteristics With an Asia-Pacific Subgroup Analysis | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 451 | Thanaporn Theerasetthumrong | Achieving Lupus Low Disease Activity State (LLDAS) and Associated Factors in Systemic Lupus Erythematosus: A 12-Year Retrospective Cohort Study | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 452 | Jianxin Tu | Targeting EBV LMP1 Affibody Molecule Screening and Its Mechanism of Regulating B Cell Proliferation in Systemic Lupus Erythematosus | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 453 | Serdal Ugurlu | Obinutuzumab for Systemic Lupus Erythematosus Patients with Rituximab Resistance or Intolerance: Case Series and Review of the Literature | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 454 | Chunyi Zhang | Targeting SIRPα Restores Macrophage Efferocytosis to Ameliorate Lupus Nephritis | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 455 | Jiuliang Zhao | Achievement and maintenance of glucocorticoid reduction without flare in Asian SLE patients with anifrolumab: Post-hoc analysis of AZALEA trial | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 456 | Hui Zhong | Evaluating DORIS remission attainment with anifrolumab in Chinese patients with active moderate-to-severe SLE: design of LOTUS, a phase 3b study | 3 | F |
| Telemedicine | 457 | Misako Higashida Konishi | Objective Assessment of Quality of Life in Patients with Rheumatoid Arthritis Using Wearable-Derived Digital Biomarkers and Machine Learning | 3 | F |
| Telemedicine | 458 | Khaiyom Mahmudzoda | Digital Monitoring of Patient-Reported Outcomes Improves Adherence and Disease Activity Control in Rheumatoid Arthritis in Tajikistan | 3 | F |
| Telemedicine | 459 | Justina Tan | SMART-RA: Telemonitoring for Stable Rheumatoid Arthritis in Routine Care | 3 | F |
| Telemedicine | 460 | Byorn Tan Wei Liang | Cross-cultural Adaptation and Expert Validation of a Telemedicine Readiness Survey in Singapore | 3 | F |
| Telemedicine | 461 | Lisa Traboco | Assisting patients & their caregivers in joint photography: Study on Infographic use in Rheumatology (APIR) | 3 | F |
| Allied health: psychological intervention and miscellaneous forms of care | 463 | Soobin Lee | Shared decision-making in autoimmune inflammatory rheumatic diseases: patient perceptions from a mixed-methods study | 3 | F |
| Allied health: psychological intervention and miscellaneous forms of care | 464 | Soobin Lee | ICT-based health information seeking among patients with autoimmune inflammatory rheumatic diseases : a mixed methods study | 3 | F |
| Rheumatoid arthritis clinical aspects and co-morbidity | 465 | Khilola Mirakhmedova | Exploring the Inflammatory and Metabolic Connection Between Rheumatoid Arthritis and MAFLD: TNF-α, IL-6, and FGF21 as Potential Biomarkers | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 466 | Tim Seabrook | An S1PR1 receptor modulator for the potential treatment of systemic lupus erythematosus and lupus nephritis | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 467 | Tim Seabrook | Transcriptional changes associated with cenerimod therapy, a selective S1PR1 modulator, in systemic lupus erythematosus: results from placebo-controlled Phase-2b CARE trial | 3 | F |
| Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies | 468 | Tim Seabrook | LUMIOS, a Phase 3 study of cenerimod for the treatment of lupus nephritis | 3 | F |
| Case reports | 469 | Jithin Mathew | A Genetic Twist to Persistent Leucopenia in a Ghanaian Girl with SLE | 3 | F |
| Case reports | 470 | Jithin Mathew | Seropositive but Not Rheumatoid: Erosive AL Amyloid Arthropathy Unmasked by Synovial Biopsy | 3 | F |
| Case reports | 471 | Sudharshan Jagennath | TAFRO Syndrome Presenting with Autoimmune Features: A Diagnostic Challenge | 3 | F |
| Case reports | 472 | Sudharshan Jagennath | When Sacroiliitis is Not Spondyloarthritis: Acute Promyelocytic Leukemia Mimicking axSpA - a case report | 3 | F |
|
